Scholarlink

Background <p>Circulating tumor DNA (ctDNA) shows promise for predicting recurrence in colorectal cancer liver metastases (CRLM) patients. We investigated the prognostic value of perioperative ctDNA, particularly 2&#xa0;week postoperative minimal residual disease (MRD), in CRLM patients undergoing liver resection.</p> Methods <p>We prospectively collected blood samples from 94 CRLM patients before (after neoadjuvant therapy, if any) and 2&#xa0;weeks after liver metastasectomy. 63 patients had both assessments. ctDNA status and variant allele fraction (VAF) were determined using targeted sequencing. Disease-free survival (DFS) was analyzed using Kaplan–Meier curves and Cox regression. Baseline characteristics were compared based on ctDNA status.</p> Results <p>Preoperative ctDNA status was not associated with DFS (<i>p</i> = 0.77). However, postoperative 2&#xa0;week MRD status was a strong predictor; MRD-positive patients (N = 31) had significantly worse DFS than MRD-negative patients (N = 32) (<i>p</i> &lt; 0.001). In multivariate analysis, postoperative MRD positivity (HR = 5.52, 95% CI: 2.46–12.39, <i>p</i> &lt; 0.001) and multiple metastases (HR = 3.42, 95% CI: 1.42–8.25, <i>p</i> = 0.006) were independent predictors of DFS. Postoperative MRD positivity showed a trend towards association with higher primary tumor T stage (<i>p</i> = 0.095). Among MRD-negative patients, a higher maximum absolute VAF change (MaxΔVAF) suggested potentially worse DFS (<i>p</i> = 0.053), while it held no prognostic value in MRD-positive patients (<i>p</i> = 0.99).</p> Conclusions <p>Postoperative 2&#xa0;week ctDNA (MRD) status is a potent, independent predictor of DFS in resected CRLM patients and outperforms preoperative ctDNA. Early MRD assessment should be considered for risk stratification and may help guide adjuvant treatment decisions. VAF dynamics might further refine prognosis, especially in MRD-negative cases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Harnessing early postoperative MRD and VAF dynamics for precision prognosis in resected colorectal liver metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Peisi Li,
  • Tuoyang Li,
  • Mingzhe Huang,
  • Yiting Liu,
  • Peiji Liu,
  • Yuanhui Wu,
  • Xuan Li,
  • Rongzhao He,
  • Yingguo Gan,
  • Yisong Hong,
  • Puning Wang,
  • Jinxin Lin,
  • Meijin Huang

摘要

Background

Circulating tumor DNA (ctDNA) shows promise for predicting recurrence in colorectal cancer liver metastases (CRLM) patients. We investigated the prognostic value of perioperative ctDNA, particularly 2 week postoperative minimal residual disease (MRD), in CRLM patients undergoing liver resection.

Methods

We prospectively collected blood samples from 94 CRLM patients before (after neoadjuvant therapy, if any) and 2 weeks after liver metastasectomy. 63 patients had both assessments. ctDNA status and variant allele fraction (VAF) were determined using targeted sequencing. Disease-free survival (DFS) was analyzed using Kaplan–Meier curves and Cox regression. Baseline characteristics were compared based on ctDNA status.

Results

Preoperative ctDNA status was not associated with DFS (p = 0.77). However, postoperative 2 week MRD status was a strong predictor; MRD-positive patients (N = 31) had significantly worse DFS than MRD-negative patients (N = 32) (p < 0.001). In multivariate analysis, postoperative MRD positivity (HR = 5.52, 95% CI: 2.46–12.39, p < 0.001) and multiple metastases (HR = 3.42, 95% CI: 1.42–8.25, p = 0.006) were independent predictors of DFS. Postoperative MRD positivity showed a trend towards association with higher primary tumor T stage (p = 0.095). Among MRD-negative patients, a higher maximum absolute VAF change (MaxΔVAF) suggested potentially worse DFS (p = 0.053), while it held no prognostic value in MRD-positive patients (p = 0.99).

Conclusions

Postoperative 2 week ctDNA (MRD) status is a potent, independent predictor of DFS in resected CRLM patients and outperforms preoperative ctDNA. Early MRD assessment should be considered for risk stratification and may help guide adjuvant treatment decisions. VAF dynamics might further refine prognosis, especially in MRD-negative cases.